Cardlytics, Inc. (NASDAQ:CDLX) Expected to Post Earnings of -$0.50 Per Share

Brokerages expect Cardlytics, Inc. (NASDAQ:CDLX) to post ($0.50) earnings per share for the current fiscal quarter, according to Zacks Investment Research. Three analysts have issued estimates for Cardlytics’ earnings, with the highest EPS estimate coming in at ($0.41) and the lowest estimate coming in at ($0.58). Cardlytics reported earnings per share of ($0.16) during the same quarter last year, which would suggest a negative year over year growth rate of 212.5%. The business is expected to announce its next quarterly earnings results on Monday, November 1st.

On average, analysts expect that Cardlytics will report full-year earnings of ($1.50) per share for the current year, with EPS estimates ranging from ($1.69) to ($1.30). For the next fiscal year, analysts forecast that the firm will post earnings of ($1.20) per share, with EPS estimates ranging from ($1.41) to ($0.98). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of analysts that follow Cardlytics.

Cardlytics (NASDAQ:CDLX) last announced its quarterly earnings results on Tuesday, August 3rd. The company reported ($0.79) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by ($0.19). The company had revenue of $58.85 million for the quarter, compared to analyst estimates of $63.23 million. Cardlytics had a negative return on equity of 15.50% and a negative net margin of 41.88%.

Several research analysts have recently issued reports on CDLX shares. TheStreet downgraded shares of Cardlytics from a “c-” rating to a “d+” rating in a report on Wednesday, August 4th. Craig Hallum lowered their price target on shares of Cardlytics from $160.00 to $120.00 and set a “buy” rating for the company in a report on Wednesday, August 4th. Zacks Investment Research upped their price target on shares of Cardlytics to $105.00 in a report on Monday, August 30th. Finally, Needham & Company LLC decreased their price objective on Cardlytics from $135.00 to $120.00 and set a “buy” rating for the company in a report on Wednesday, August 4th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and three have issued a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $129.00.

In other Cardlytics news, Director S Aimee Lapic sold 3,176 shares of the stock in a transaction dated Monday, June 28th. The stock was sold at an average price of $127.32, for a total transaction of $404,368.32. Following the completion of the sale, the director now directly owns 6,198 shares in the company, valued at approximately $789,129.36. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, major shareholder Clifford Sosin acquired 370,619 shares of the business’s stock in a transaction dated Thursday, August 5th. The shares were bought at an average cost of $87.07 per share, for a total transaction of $32,269,796.33. The disclosure for this purchase can be found here. Over the last 90 days, insiders purchased 372,619 shares of company stock valued at $32,438,256 and sold 27,802 shares valued at $2,990,041. Corporate insiders own 6.50% of the company’s stock.

Hedge funds have recently added to or reduced their stakes in the company. State Board of Administration of Florida Retirement System lifted its position in Cardlytics by 1.2% in the 1st quarter. State Board of Administration of Florida Retirement System now owns 10,497 shares of the company’s stock valued at $1,152,000 after acquiring an additional 120 shares in the last quarter. Prudential Financial Inc. lifted its position in Cardlytics by 6.4% in the 2nd quarter. Prudential Financial Inc. now owns 2,670 shares of the company’s stock valued at $339,000 after acquiring an additional 160 shares in the last quarter. Amalgamated Bank lifted its position in Cardlytics by 4.0% in the 1st quarter. Amalgamated Bank now owns 4,252 shares of the company’s stock valued at $466,000 after acquiring an additional 162 shares in the last quarter. US Bancorp DE lifted its position in Cardlytics by 245.7% in the 2nd quarter. US Bancorp DE now owns 242 shares of the company’s stock valued at $31,000 after acquiring an additional 172 shares in the last quarter. Finally, UBS Group AG lifted its position in Cardlytics by 10.3% in the 1st quarter. UBS Group AG now owns 2,212 shares of the company’s stock valued at $242,000 after acquiring an additional 207 shares in the last quarter. 94.51% of the stock is currently owned by institutional investors.

Shares of NASDAQ:CDLX opened at $96.45 on Wednesday. The company has a fifty day moving average of $98.22 and a 200-day moving average of $109.77. The company has a market capitalization of $3.19 billion, a PE ratio of -31.31 and a beta of 2.54. The company has a debt-to-equity ratio of 0.35, a quick ratio of 1.29 and a current ratio of 1.29. Cardlytics has a 52-week low of $64.20 and a 52-week high of $161.47.

About Cardlytics

Cardlytics, Inc engages in the development of marketing solutions through its purchase intelligence platform. It operates through the Cardlytics Direct and Other Platform Solutions segments. The Cardlytics Direct segment represents its proprietary native bank advertising channel. The Other Platform Solutions segment includes solutions that enable marketers and marketing service providers to leverage the power of purchase intelligence outside the banking channel.

Recommended Story: Stock Symbols, CUSIP and Other Stock Identifiers

Get a free copy of the Zacks research report on Cardlytics (CDLX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Cardlytics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardlytics and related companies with MarketBeat.com's FREE daily email newsletter.